Product name:Imatinib

Alias: 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE;Imatinib(4- [(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide;Imatinibfreebase;Veenat;IMatinib(STI571) ;Imantinibbase;4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM;IMatinib-D4

CAS No.:152459-95-5

Molecular formula: C29H31N7O

Molecular weight: 493.6

Structural formula:

Description: Imatinib is an oral drug for the treatment of adult patients with Philadelphia chromosome (Ber-Abl) positive chronic myeloid leukemia (CML) in blast phase, accelerated phase and chronic phase after failure of interferon therapy.